Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Standard
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. / Alchalby, Haefaa; Badbaran, Anita; Zabelina, Tatjana; Kobbe, Guido; Hahn, Joachim; Wolff, Daniel; Bornhäuser, Martin; Christian, Thiede; Baurmann, Herrad; Bethge, Wolfgang; Hildebrandt, York; Bacher, Ulrike; Fehse, Boris; Zander, Axel R.; Kröger, Nicolaus.
In: BLOOD, Vol. 116, No. 18, 18, 2010, p. 3572-3581.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
AU - Alchalby, Haefaa
AU - Badbaran, Anita
AU - Zabelina, Tatjana
AU - Kobbe, Guido
AU - Hahn, Joachim
AU - Wolff, Daniel
AU - Bornhäuser, Martin
AU - Christian, Thiede
AU - Baurmann, Herrad
AU - Bethge, Wolfgang
AU - Hildebrandt, York
AU - Bacher, Ulrike
AU - Fehse, Boris
AU - Zander, Axel R.
AU - Kröger, Nicolaus
PY - 2010
Y1 - 2010
N2 - Allogeneic stem cell transplantation (ASCT) after reduced-intensity conditioning has become a reasonable treatment option for patients with advanced myelofibrosis. The role of characteristic molecular genetic abnormalities, such as JAK2V617F on outcome of ASCT, is not yet elucidated. In 139 of 162 myelofibrosis patients with known JAK2V617F mutation status who received ASCT after reduced-intensity conditioning, the impact of JAK2 genotype, JAK2V617F allele burden, and clearance of mutation after ASCT was evaluated. Overall survival was significantly reduced in multivariate analysis in patients harboring JAK2 wild-type (hazard ratio = 2.14, P = .01) compared with JAK2 mutated patients. No significant influence on outcome was noted for the mutated allele burden analyzed either as continuous variable or after dividing into quartiles. Achievement of JAK2V617F negativity after ASCT was significantly associated with a decreased incidence of relapse (hazard ratio = 0.22, P = .04). In a landmark analysis, patients who cleared JAK2 mutation level in peripheral blood 6 months after ASCT had a significant lower risk of relapse (5% vs 35%, P = .03). We conclude that JAK2V617F-mutated status, but not allele frequency, resulted in an improved survival and rapid clearance after allografting reduces the risk of relapse.
AB - Allogeneic stem cell transplantation (ASCT) after reduced-intensity conditioning has become a reasonable treatment option for patients with advanced myelofibrosis. The role of characteristic molecular genetic abnormalities, such as JAK2V617F on outcome of ASCT, is not yet elucidated. In 139 of 162 myelofibrosis patients with known JAK2V617F mutation status who received ASCT after reduced-intensity conditioning, the impact of JAK2 genotype, JAK2V617F allele burden, and clearance of mutation after ASCT was evaluated. Overall survival was significantly reduced in multivariate analysis in patients harboring JAK2 wild-type (hazard ratio = 2.14, P = .01) compared with JAK2 mutated patients. No significant influence on outcome was noted for the mutated allele burden analyzed either as continuous variable or after dividing into quartiles. Achievement of JAK2V617F negativity after ASCT was significantly associated with a decreased incidence of relapse (hazard ratio = 0.22, P = .04). In a landmark analysis, patients who cleared JAK2 mutation level in peripheral blood 6 months after ASCT had a significant lower risk of relapse (5% vs 35%, P = .03). We conclude that JAK2V617F-mutated status, but not allele frequency, resulted in an improved survival and rapid clearance after allografting reduces the risk of relapse.
M3 - SCORING: Zeitschriftenaufsatz
VL - 116
SP - 3572
EP - 3581
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 18
M1 - 18
ER -
